Topical Minoxidil Side Effects: Potentially Permanent Side Effects Explained
At a glance
- Permanence on the labels / no listed effect is described as permanent on the topical labels [1][2]
- Hair gained / lost again if use stops; the labels say continued use is needed to keep regrowth [1][2]
- Unwanted facial hair / on both labels' stop-use lists [1][2]
- After stopping / a review says measurable changes disappear within months of discontinuation [3]
- Scalp irritation / more pruritus and irritation with 5% than 2% in a 48-week trial of 381 women [4]
- Skin absorption / about 1.4% of a topical dose is absorbed through the skin [5]
- Heart warnings / heart disease flagged before use; stop-use list includes chest pain, rapid heartbeat, faintness, dizziness, weight gain and swelling [1][2]
- Pregnancy and breastfeeding / labels say may be harmful if used when pregnant or breast-feeding [1][2]
- Allergy / allergic contact dermatitis reported, including to propylene glycol in some solutions [3]
Does topical minoxidil cause permanent side effects?
The topical labels do not describe their listed effects as permanent. The Drug Facts for the men's 5% solution and the women's products put scalp irritation or redness, unwanted facial hair growth, chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, and swelling of the hands or feet on the stop-use list [1][2]. A review of minoxidil's adverse effects reports that measurable changes disappear within months after treatment stops, but it does not establish a recovery timeline for every one of those warnings [3].
What the labels warn about
The men's 5% solution is labeled for men only, for the top of the scalp (vertex) only, and not for frontal baldness or a receding hairline. Its do-not-use list covers people under 18, no family history of hair loss, sudden or patchy hair loss, an unknown reason for hair loss, a scalp that is red, inflamed, infected, irritated or painful, and use of other medicines on the scalp. Heart disease is named as well, as a condition the label flags before use [1]. The women's label also lists hair loss associated with childbirth among the reasons not to use the product [2].
Unwanted facial hair: does it reverse?
Hypertrichosis means extra or darker fine hair away from the scalp [3]. In a 48-week double-blind trial of 381 women with female pattern hair loss, the 5% solution beat placebo on hair count but produced more pruritus, irritation and hypertrichosis than the 2% solution or placebo [4].
Both labels list unwanted facial hair growth on their stop-use lists [1][2]. The review reports that measurable changes disappear within months of discontinuation, without saying whether that includes facial hair [3].
The scalp benefit itself depends on continued use: the labels state that continued use is necessary to increase and keep regrowth, or hair loss will begin again [1][2].
Scalp irritation, and the allergy
The review says the most common adverse reactions of the topical formulation are irritant and allergic contact dermatitis on the scalp [3]. Irritation was more frequent with the higher concentration in both trials: the 5% solution produced more pruritus and local irritation than the 2% solution in a 48-week trial of 393 men [7], and the 48-week trial of 381 women found more pruritus and irritation with 5% than with 2% or placebo [4].
The vehicle matters. There are reported cases of allergic reaction to propylene glycol, a non-active ingredient in some topical solutions [3]. The 5% foam uses a propylene glycol-free vehicle and was well tolerated over a 52-week open-label follow-up of 143 men [8]. Allergic contact dermatitis is an immune reaction, and the propylene glycol cases the review describes were allergic reactions [3].
Why shedding can happen during use
The review says minoxidil can cause follicles in the telogen phase to shed, usually soon to be replaced by new, thicker hairs in a new anagen phase, and attributes the increased hair loss that can occur during use to synchronization of the hair cycle [3]. In animal studies, topical minoxidil shortened telogen, causing premature entry of resting follicles into the growth (anagen) phase, and it probably has a similar action in humans [9]. The men's label puts results at 2 months for some men using the product twice a day and says at least 4 months may be needed [1]; the women's label puts results at 3 months, with up to 6 months for some women [2].
Heart symptoms the labels list
The topical labels list chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, and swelling of the hands or feet on the stop-use list [1][2]. A review estimates that about 1.4% of topically applied minoxidil is absorbed through the skin [5].
Pregnancy and breastfeeding
Both labels state that the product may be harmful if used when pregnant or breast-feeding [1][2].
Stopping minoxidil
If topical minoxidil use stops, the labels say hair loss will begin again because continued use is needed to keep the regrowth [1][2].
Frequently asked questions
Are minoxidil side effects permanent?
Does unwanted facial hair from minoxidil go away?
Can topical minoxidil cause permanent hair loss?
Can I become allergic to minoxidil after using it for a while?
Is the 5% solution harsher on the scalp than 2%?
What heart symptoms do the minoxidil labels warn about?
References
- U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
- U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
- Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-6. Minoxidil use in dermatology, side effects and recent patents
- Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
- Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022;33(4):1896-1906. Minoxidil: a comprehensive review
- U.S. Food and Drug Administration. U.S. Food and Drug Administration
- Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
- Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-94. Minoxidil: mechanisms of action on hair growth
- Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
- Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160(6):600-605. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial